Evolocumab Pharmacokinetics in Healthy Subjects

This trial aims to study how two versions of the drug evolocumab move through the body in healthy individuals. Researchers are testing evolocumab to better understand its effects. Participants will receive a single injection of one of the two evolocumab products. Individuals with an LDL cholesterol level between 70 and 190 mg/dL and no history of heart issues might be suitable for this trial. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants a chance to contribute to early-stage medical research.

Yes, you will need to stop taking any over-the-counter or prescription medications, herbal medicines, vitamins, and supplements at least 30 days before the trial starts.

Research has shown that evolocumab is generally safe for people. In earlier studies, many patients reported mild side effects such as colds and sore throats, which were often similar to those experienced by people taking a placebo, a harmless pill with no real effect.

In another study, 69.2% of patients taking evolocumab experienced some side effects, but these were mostly mild and similar to those in people not taking the drug. Serious side effects were rare.

Researchers are excited about evolocumab because it represents a promising advance in cholesterol management. Unlike traditional statins that work by blocking an enzyme in the liver, evolocumab is a monoclonal antibody that targets and inhibits a protein called PCSK9. This unique mechanism helps the liver remove more LDL cholesterol from the blood. Additionally, evolocumab is administered through a simple subcutaneous injection, which could offer a convenient alternative for patients who struggle with daily oral medications.

Research has shown that evolocumab effectively lowers LDL cholesterol, often referred to as "bad cholesterol." Studies have found that it can reduce LDL levels by 53% to 75%. In one study, a 140 mg dose of evolocumab reduced LDL cholesterol by 66% over 10 to 12 weeks. Another study found that doses of 140 mg and 420 mg reduced LDL cholesterol by up to 71%. This trial will evaluate the pharmacokinetics of two different formulations of evolocumab, labeled as Drug Substance A and Drug Substance B, in healthy subjects. This treatment has shown promising results in managing cholesterol levels, making it an important option for those at risk of heart disease.⁶⁷⁸⁹¹⁰